• Department of Pediatric Transplantation, Tianjin First Central Hospital/Tianjin Key Laboratory for Organ Transplantation, Tianjin 300192, P. R. China;
GAO Wei, Email: gaowei_tjfch@163.com
Export PDF Favorites Scan Get Citation

Objective To compare the effect and safety of basiliximab in ABO incompatible pediatric liver transplant recipients.Methods ABO incompatible pediatric liver transplantation operated between January 2019 and August 2020 were studied. The patients were allocated randomized into two groups. Patients in experimental group were treated with basiliximab as immune induction therapy, but basiliximab was not used in patients of control group. Tacrolimus combined methylprednisolone were used after liver transplantation. The clinical characteristics, graft and recipient survival rate, rejection, infectious complications, and kidney functions after liver transplantation were observed. Donor specific antibody (DSA) was tested in 3 months after liver transplantation. The growth and development were assessed too after liver transplant.Results Fourty-four patients were enrolled in the study, including 19 patients in the experimental group and 25 patients in the control group. The median follow-up time was 16.6 months (3.8–25.4 months), and there were no statistically differences between the two groups in terms of age, sex, weight, pediatric end-stage liver disease (PELD) score, and other basic conditions. There were no significant differences between the two groups in tacrolimus dose, tacrolimus trough concentration, kidney functions, height and weight growth after liver transplantation. There were no statistical differences in lung infection, blood stream infection within 3 months after liver transplantation, cytomegalovirus, EBV infection, graft/patient survival rate after liver transplantation (P>0.05). However, the acute rejection rate was lower and the DSA positive rate in 3 months after liver transplantation was lower in the experimental group (P<0.05).Conclusions Basiliximab can be safely used in ABO incompatible pediatric liver transplant recipients. Acute rejection rate and DSA positive rate after transplantation can be decreased with the useof basiliximab.

Citation: SUN Chao, DONG Chong, ZHENG Weiping, WANG Kai, QIN Hong, YANG Yang, HAN Chao, ZHANG Fubo, SONG Zhuolun, CAO Shunqi, XU Min, GAO Wei. Randomized controlled trial of the application of basiliximab in ABO incompatible pediatric liver transplantation: preliminary results. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(8): 997-1002. doi: 10.7507/1007-9424.202103064 Copy

  • Previous Article

    Clinical effect of perioperative intravenous immunoglobulin on ABO incompatible liver transplantation
  • Next Article

    Hybrid or open surgery for aortic arch diseases: Which one is better?